Synthesis of a novel amphiphilic GdPCTA-[12] derivative as a potential micellar MRI contrast agent

A novel amphiphilic contrast agent, a GdPCTA-[12] derivative containing a dodecyl chain as lipophilic moiety, has been prepared. A convergent synthetic route from commercially available diethylene triamine and 3-hydroxypyridine is described. The target amphiphilic gadolinium complex was obtained in nine steps in 22% overall yield. Physicochemical properties and relaxivity measurements of this new contrast agent are described.     

Synthesis of a tricyclic tetraazatriacetic ligand for gadolinium(III) as potential contrast agent for MRI

A tricyclic tetraazatriacetic compound, which is a rigidified derivative of PCTA12 ligand with a cyclohexylene bridge replacing an ethylene one, was prepared. Two synthetic routes have been investigated, both of them implying a common functionalized triamine intermediate. Whatever the route, four synthetic steps were necessary to obtain the target tricyclic ligand. The more effective one (Route B) led to the desired compound in 19% overall yield from the triamine intermediate. The corresponding gadolinium complex of 1/1 stoichiometry was then prepared in order to evaluate it as potential contrast agent for MRI.     

Synthesis of Gd-DTPA-cholesterol: a new lipophilic gadolinium complex as a potential MRI contrast agent

A straightforward and efficient synthesis of Gd-DTPA-cholesterol is reported. This new lipophilic gadolinium complex can be easily incorporated into mixed micelles in order to achieve MRI contrast agents with increased relaxivity. These supramolecular systems can find potential application in magnetic resonance angiography (MRA).     

Synthesis, binding affinity, and relaxivity of target-specific MRI contrast agents

Although magnetic resonance imaging (MRI) is one of the most important imaging modalities of the central nervous system (CNS), one of the main drawbacks of MRI is its limited specificity. This can potentially be partially alleviated by target-specific contrast agents. In the present paper we describe a simple high yield synthesis of two such gadolinium-based spiperone targeted MRI contrast agents, 1a and 1b. The R₁ relaxivities of 1a and 1b were evaluated and found to be 5.94 and 8.31 mM⁻¹ s⁻¹, respectively at 9.4T, while their R₂ relaxivities at the same magnetic field were found to be 18.05 and 22.60 mM⁻¹ s⁻¹, respectively. In addition and very importantly compound 1a, which is a gadolinium-based, spiperone-targeted MRI contrast agent, was found to preserve some of the spiperone affinity toward the dopamine D2 receptor. Compounds 1a and 1b thus represent potential agents for in vitro dopamine receptor imaging using MRI in experimental models. Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users.     

Synthesis, characterization, and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centers with albumin binding affinity

A dinuclear gadolinium(III) complex of an amphiphilic chelating ligand, containing two diethylenetriamine-N,N,N',N',N'-pentaacetate (DTPA) moieties bridged by a bisindole derivative with three methoxy groups, has been synthesized and evaluated as a potential magnetic resonance imaging (MRI) contrast agent. Nuclear magnetic relaxation dispersion (NMRD) measurements indicate that at 20 MHz and 37 degrees C the dinuclear gadolinium(III) complex has a much higher relaxivity than [Gd(DTPA)] (6.8 vs 3.9 s(-1) mmol(-1)). The higher relaxivity of the dinuclear gadolinium(III) complex can be related to its reduced motion and larger rotational correlation time relative to [Gd(DTPA)]. In the presence of human serum albumin (HSA) the relaxivity value of the noncovalently bound dinuclear complex increases to 15.2 s(-1) per mmol of Gd3+, due to its relatively strong interaction with this protein. The fitted value of the binding constant to HSA (Ka) was found to be 10(4) M(-1). Because of its interaction with HSA, the dinuclear complex exhibits a longer elimination half-life from the plasma, and a better confinement to the vascular space compared to the commercially available [Gd(DTPA)] contrast agent. Transmetalation of the dinuclear gadolinium(III) complex by zinc(II) has been investigated. Biodistribution studies suggest that the complex is excreted by the renal pathway, and possibly by the hepatobiliary route. In vivo studies indicated that half of the normal dose of the gadolinium(III) complex enhanced the contrast in hepatic tissues around 40 % more effectively than [Gd(DTPA)]. The dinuclear gadolinium(III) complex was tested as a potential necrosis avid contrast agent (NACA), but despite the binding to HSA, it did not exhibit necrosis avidity, implying that binding to albumin is not a key parameter for necrosis-targeting properties.     

Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent

The design of effective pH responsive MRI contrast agents is a key goal in the development of new diagnostic methods for conditions such as kidney disease and cancer. A key factor determining the effectiveness of an agent is the difference between the relaxivity of the "on" state compared to that of the "off" state. In this paper, we demonstrate that it is possible to improve the pH-responsive action of a low molecular weight agent by conjugating it to a macromolecular construct. The synthesis of a bifunctional pH responsive agent is reported. As part of that synthetic pathway we examine the Ing-Manske reaction, identifying an undesirable by-product and establishing effective conditions for promoting a clean and effective reaction. Reaction of the bifunctional pH responsive agent with a G5-PAMAM dendrimer yielded a product with an average of 96 chelates per dendrimer. The relaxivity of the dendrimer conjugate rises from 10.8 mM(-1) s(-1) (pH 9) to 24.0 mM(-1) s(-1) (pH 6) per Gd(3+) ion. This more than doubles the relaxivity pH response, Deltar(1), of our agent from just 51 % for the original low molecular weight chelate to 122 % for the dendrimer.     

Synthesis and characterization of a redox- and light-sensitive MRI contrast agent

A redox- and light-sensitive, T₁-weighted magnetic resonance imaging (MRI) contrast agent, which tethers a spiropyran (SP)/merocyanine (MC) motif to a Gd-DO3A moiety was synthesized and characterized. When in the dark, the probe is in its MC form, which has an r₁ relaxivity of 2.51 m M⁻¹ s⁻¹ (60 MHz, 37 °C). After irradiation with visible light or mixing with NADH, the probe experiences an isomerization and the r₁ relaxivity decreased 18% and 26%, respectively. Additionally, the signal intensity in MRI showed an observable decrease after the compound was mixed with NADH.     

Synthesis and in vitro studies of Gd-DTPA derivatives as new potential MRI contrast agents

A new type of dendritic molecules, Gd-DTPA derivatives, which work as a functionalized ligand coordinating gadolinium(III) ion at the center of their frameworks with different terminal moieties on the molecular surfaces, was readily synthesized with high yield. The structures were established by ¹H, ¹³C NMR, and mass spectral studies. In vitro studies showed them to have enhanced r₁ value in albumin medium and good potentiality as MRI contrast agent.     

Synthesis of Two N,N′-bis(N,N-dialkylamide) Derivatives of Diethylenetriaminepentaacetic Acid and the Stabilities of Their Complexes with Gd3+, Ca2+, Cu2+, and Zn2+

Two bis(N,N-dialkylamide) derivatives of DTPA [(carboxymethyl)iminobis (ethylenenitrilo) tetraacetic acid], DTPA-BDMA = the bis(N,N-dimethylamide) and DTPA-BDEA = the bis(N,N-diethylamide) were synthesized. Their protonation constants were determined by potentiometric titration in 0.10 M Me₄NNO₃ and by NMR pH titration at 25.0 ± 0.1 °C. Stability and selectivity constants were measured to evaluate the possibility of using the corresponding gadolinium(III) complexes for magnetic resonance imaging contrast agents. The stability constants of gadolinium(III), copper(II), zinc(II), and calcium(II) complexes with DTPA-BDMA and DTPA-BDEA were investigated quantitatively by potentiometry. The stability constant for gadolinium(III) complexes is larger than those for Ca(II), Zn(II), and Cu(II) complexes. The selectivity constants and modified selectivity constants of the amides for Gd³⁺ over endogenously available metal ions were calculated. Effectiveness of these two ligands in binding divalent and trivalent metal ions in biological media is assessed by comparing pM values at physiological pH 7.4. Spin-lattice relaxivity values R₁ for Gd(III) complexes were also determined. The observed relaxivity values were found to decrease with increasing pH in the acid range below pH 4 and relaxivity values became invariant with respect to pH changes over the range of 4–10. ¹⁷O NMR shifts showed that the [Dy(DTPA-BDMA)] and [Dy(DTPA-BDEA)] complexes had one inner-sphere water molecule. Water proton spin-lattice relaxation rates for the [Gd(DTPA-BDMA)] and [Gd(DTPA-BDEA)] complexes were also consistent with one inner-sphere gadolinium(III) coordination position.     

High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-beta-cyclodextrin

Nanosized contrast agents have great potential in magnetic resonance molecular imaging applications for clinical diagnosis. This study proposes new nanoparticles spontaneously formed under mild conditions and composed of a noncovalent adduct between a gadolinium complex, a polymer of beta-cyclodextrin (pbetaCD: MW 1.5 x 10(6) g mol(-1)) and a dextran grafted with alkyl chains (MD). The formation of this supramolecular nanoassembly is based upon a "lock-and-key" recognition process in which the hydrophobic alkyl chains of MD and the adamantyl moieties of macrocyclic Gd(III) chelates are included in the cavities of pbetaCD. The large number of betaCDs contained in the pbetaCD resulted in the formation of 200 nm diameter nanoparticles, each entrapping 1.8 x 10(5) molecules of a low-molecular-weight Gd complex. This system, which exhibits a great relaxivity enhancement (48.4 mM(-1) s(-1), at 20 MHz and 37 degrees C) compared to the Gd(III) chelate itself (5.2 mM(-1) s(-1)), appears to be a promising strategy for the in vivo targeted delivery of Gd(III) complexes. The mechanisms of particle formation, conjugation strategies, and relaxometric characterizations in the field of contrast-enhanced magnetic resonance imaging are discussed.     

Synthesis and crystal structure of a new oxamidato-bridged trinuclear Cu2 II MnII complex containing a macrocyclic ligand

A new oxamidato-bridged trinuclear complex [(CuL)₂Mn](ClO₄)₂ (H₂L = 2,3-dioxo-5,6,14,15-dibenzo-1,4, 8,12-tetraazacyclo-pentadeca-7,3-dien)] was prepared and its structure determined. The complex is monoclinic, space group P2₁/n, with a = 10.625(3), b = 11.602(3), c = 16.020(5)?Å, β = 91.031(5)°, Z = 2; it was refined to R1 = 0.0555. In the solid state, the structure consists of centrosymmetric [(CuL)₂Mn]²⁺ cations separated by perchlorate anions; the central manganese atom is four coordinated with square planar geometry.     

Synthesis of an hexadentate tricyclic tetraazadiacetic ligand as precursor for MRI contrast enhancement agents

A tricyclic tetraazadiacetic compound, which is a rigidified derivative of cyclo-PCTA12 ligand with an oxo-ethylene bridge replacing an ethylene one, was prepared. The synthetic route involved the macrocyclization between an activated amido-disulfonamide and the 2,6-bis(bromomethyl)pyridine. The acetate side chains were grafted on the macrocyclic backbone to lead to the highly rigid tricyclic ligand in 34% overall yield in four steps from the linear amido-disulfonamide precursor. The corresponding Gd(III) and Mn(II) complexes were then prepared in order to evaluate their potential as contrast agent for MRI.     

Synthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus

A new site-targeted molecular imaging contrast agent based on a nanocolloidal suspension of lipid-encapsulated, organically soluble divalent copper has been developed. Concentrating a high payload of divalent copper ions per nanoparticle, this agent provides a high per-particle r1 relaxivity, allowing sensitive detection in T1-weighted magnetic resonance imaging when targeted to fibrin clots in vitro. The particle also exhibits a defined clearance and safety profile in vivo.     

Some new DTPA-N,N″-bis(amides) functionalized by alkyl carboxylates: Synthesis,complexation and stability properties

A new series of DTPA-N,N″-bis(amide) ligands functionalized by alkyl carboxylates on the amide side-arms (1a–1l) and their Gd(III) complexes of the type [Gd(1)(H₂O)] · xH₂O (2a–2l) were synthesized and characterized by analytical and spectroscopic techniques. Potentiality of 2a–2l as contrast agent for magnetic resonance imaging (MRI CA) was investigated by measuring some relevant physicochemical properties such as (i) the protonation constants of 1a–1l, (ii) thermodynamic and conditional stability constants of 2a–2l, (iii) the selectivity (pGd) of 1a–1l for the Gd(III) ion over the endogenous metal ions such as Zn(II), Ca(II), and Cu(II), and (iv) the relaxivities (R₁ and R₂) of 2a–2l in aqueous and aqueous HP-β-CD solutions. Comparative studies reveal that most of new Gd(III) complexes show enhanced thermodynamic stability and selectivity as compared with those of [Gd(DTPA-BMA)(H₂O)] (DTPA-BMA = N,N″-di(methylcarbamoylmethyl)diethylenetriamine-N,N′,N″-triacetate). Also enhanced with 1a–1l (except 1f and 1h) is affinity for Gd(III) as compared with [DTPA-BMA]³⁻ under physiological conditions. The relaxivities (R₁ and R₂) of aqueous solutions of 2a–2l, on the other hand, drop significantly as compared with [Gd(DTPA-BMA)(H₂O)] although they increase dramatically (6–10 fold) in aqueous hydroxypropyl-β-cyclodextrin (HP-β-CD) solutions.     

Synthesis of a new tricyclic tetraazatriacetic acid as ligand for gadolinium(III)

Polyazapolycarboxylic acids are known to be efficient ligands for the development of gadolinium-based contrast agents used in magnetic resonance imaging (MRI). Given that rigidification of the ligand structure seems to be an important structural parameter to increase the relaxivity of the corresponding gadolinium complex, we have synthesized a new tricyclic tetraazatriacetate ligand from commercially available trans-2-aminocyclohexanol. In the synthetic routes described here, the 2-nitrobenzenesulfonamide chemistry was used to selectively functionalize the polyamine precursors.     

Synthesis,radiolabeling and biological distribution of a new dioxime derivative as a potential tumor imaging agent

A novel dioxime derivative (2E,2′E,3E,3′E)-3,3′-(pyrimidine-4,5-diylbis(azanylylidene))bis(butan-2-one)dioxime was synthesized with a yield of 65%. IR, elemental analysis, mass spectroscopy and ¹H-NMR were used to characterize the structure of the synthesized compound. ^99mTc-dioxime was radio-synthesized with a high radiochemical yield of 97.8 ± 0.5% and in vitro stability of 6 h under the optimum conditions. The preclinical evaluation of ^99mTc-dioxime in solid tumor-bearing mice showed high accumulation in solid tumor cells with a high Target/Non-Target ratio of 5.14 at 30 min post-injection. This study suggests that ^99mTc-dioxime derivative is a promising candidate as a new ^99mTc-based tumor-imaging agent after further preclinical studies.